The potential for cell and gene therapies is growing, offering groundbreaking treatments for rare genetic disorders and ...

Gastrointestinal cancers continue to pose a significant global health challenge, with limited effective treatment options and ...

Peeyush Khandelwal highlights that the future of AI in healthcare depends on a balance between innovation, workforce ...

Outranked only by skin cancer, prostate cancer is the second most common cancer in men in the U.S. Although one in every ...

The FDA cleared the firm this week to begin a Phase I study of ALX2004 in EGFR-expressing solid tumors, which could start in a few months.

The field of gynecologic oncology has seen remarkable progress in recent years, driven by technological innovations and the integration of multidisciplinary ...

Precision for Medicine, a leading provider of drug development and commercialization services, today announced a strategic partnership with SOPHiA GENETICS to enhance its biomarker discovery and ...

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials ...

Signios Biosciences ("Signios Bio"), a science-first biotechnology company at the forefront of multiomics and AI-powered ...

Strategic Combination Intended to Drive Advanced AI-Driven Drug Development and Expand Precision Medicine Applications Across Cancer and ...